mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
Por:
Albiol, N, Barata, A, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I
Publicada:
1 dic 2022
Ahead of Print:
1 sep 2022
Resumen:
Purpose This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. Methods We performed a single-center prospective study including recently transplanted (< 2 years post-infusion) allogeneic HCT recipients. AEs were assessed through phone calls and graded from 0 to 4, while COVID-19 risk perception was measured using the Brief Illness Perception Questionnaire (BIP-Q5). Results Fifty-four HCT recipients were evaluated. Incidence and grades of AE (94.4% and 85.2% after the first and second dose, respectively) were similar to those described in the general population. The most common AE was pain at the site of injection. Three patients (5.6%) developed a grade >= 3 AE. Vaccine-related cytopenias and graft-versus-host disease flares were not observed. Female sex (OR 3.94, 95% CI 1.14-13.58, p = 0.03) and time since HCT (per month since HCT: OR 1.09, 95% CI 1.01-1.18, p = 0.04) were associated with the occurrence of any AE. The patients' risk perception level of COVID-19 decreased over time (p < 0.05). Conclusion Our study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time.
Filiaciones:
Albiol, N:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Barata, A:
H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
Aso, O:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Gomez-Perez, L:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Triquell, M:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Roch, N:
H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
Lazaro, E:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Esquirol, A:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Gonzalez, I:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Lopez-Contreras, J:
Autonomous Univ Barcelona, Barcelona, Spain
Hosp La Santa Creu & St Pau, Infect Dis Dept, Barcelona, Spain
Sierra, J:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Martino, R:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Garcia-Cadenas, I:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Green Published, Bronze, All Open Access, Green
|